Windtree Therapeutics Files 2024 Proxy Statement

TL;DR

Windtree Therapeutics proxy statement is out - time to vote on directors and auditors.

AI Summary

Windtree Therapeutics, Inc. filed a DEF 14A proxy statement on September 3, 2024, for its annual meeting of stockholders. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership and voting matters, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine annual filing providing information to shareholders and does not inherently present new risks.

Key Players & Entities

• WINDTREE THERAPEUTICS INC /DE/ (company) — Registrant
• 0001437749-24-028207 (filing_id) — Accession Number
• 20240903 (date) — Filing Date
• 20240924 (date) — Period of Report
• 2836 (sic_code) — Standard Industrial Classification
• 2154889300 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $138 million — ceive potential future milestones up to $138 million upon the achievement of certain milesto
• $15 million — thened its balance sheet by eliminating $15 million in deferred liabilities with affiliates
• $0.001 — Convertible Preferred Stock, par value $0.001 per share, or Series C Convertible Pref
• $3 — ck, with an initial conversion price of $3.74, which is subject to adjustment to n
• $1.28 — subject to adjustment to no lower than $1.28 per share, and (ii) the exercise of war
• $4 — with, with an initial exercise price of $4.11, subject to customary adjustments; a
• $11,950 — tion of proxies for an estimated fee of $11,950. We may also reimburse brokerage firms,

Filing Documents

• wint20240830_def14a.htm (DEF 14A) — 805KB
• graph01.jpg (GRAPHIC) — 35KB
• graph02.jpg (GRAPHIC) — 31KB
• pc01.jpg (GRAPHIC) — 239KB
• pc02.jpg (GRAPHIC) — 186KB
• wt01.jpg (GRAPHIC) — 10KB
• wt02.jpg (GRAPHIC) — 2KB
• wt03.jpg (GRAPHIC) — 2KB
• wt04.jpg (GRAPHIC) — 3KB
• wt05.jpg (GRAPHIC) — 27KB
• 0001437749-24-028207.txt ( ) — 1545KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 23 PAY VERSUS PERFORMANCE 30 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 33

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 35 EQUITY COMPENSATION PLAN INFORMATION 37 ITEMS TO BE VOTED ON 38 OTHER INFORMATION 49 Notice of Annual Meeting of Stockholders and 2024 Proxy Statement iii Table of Contents PROXY STATEMENT This Proxy Statement, with the enclosed proxy card, is being furnished to stockholders of Windtree in connection with the solicitation by our Board of proxies to be voted at our Annual Meeting and at any postponements or adjournments thereof. The Annual Meeting will be held virtually on Tuesday, September 24, 2024, at 9:00 a.m., Eastern Time via live webcast by visiting https://www.cstproxy.com/windtreetx/2024 . This Proxy Statement and the enclosed proxy card are first being mailed to our stockholders on or about September 3, 2024. Notice of Annual Meeting of Stockholders and 2024 Proxy Statement iv Table of Contents GENERAL INFORMATION ABOUT THE MEETING PROXY SOLICITATION Windtree is soliciting your vote on matters that will be presented at the Annual Meeting and at any adjournment or postponement thereof. This Proxy Statement contains information on these matters to assist you in voting your shares. This Proxy Statement and the proxy card are first being furnished to our stockholders on or about September 3, 2024. This Proxy Statement and our 2023 Annual Report are available to holders of our common stock at https://www.cstproxy.com/windtreetx/2024 and on our corporate website at www.windtreetx.com . STOCKHOLDERS ENTITLED TO VOTE All stockholders of record of our common stock at the close of business on August 28, 2024, or the Record Date, are entitled to receive the Notice and to vote their shares at the Annual Meeting. As of the Record Date, 591,909 shares of our common stock were outstanding. Each share is entitled to one vote on each matter properly brought to the meeting. As of the Record Date, no shares of common stock were issued under the Committed Equity Financing as disc

View Full Filing

View this DEF 14A filing on SEC EDGAR